Targeted inhibition of the SHCBP1‐PLK1 axis can not only reduce bone metastasis but also sensitize docetaxel chemotherapy, reducing the increased side effects of multi‐drug combination treatment in PCa patients with bone metastasis. Here, SHCBP1 is linked to posterior cortical atrophy.